Cochlear Limited posted both positive and negative Cochlear HY26 financial results, with the rollout of the Nexa System creating a first-half trading period. The sales revenue increased by 1 per cent to 1176m and declined by 2 per cent in constant currency.
The underlying net profit decreased by 9 per cent to $195m. The management attributed the downtrend to slower shrinking and registration in the developed markets. The firm advocated price increments in renewal.
This was not as quick as it should have been. It started in June 2025 and targeted the Nucleus Nexa System. The product is the first upgradeable firmware smart cochlear implant.
Although there were delays, there was better adoption towards the end of the half. About 80 per cent of the units utilised the new system in December. Net cash remained strong at $173m. The interim dividend was maintained at $ 2.15 per share.
The Nucleus Nexa System launch by Cochlear, helps sustain the long-term growth plan. [The Hearing Review]
Sales Revenue Edges Higher Despite Currency Pressure
Group revenue also increased to $1,176m as the gross margin declined to 73%. Selling, marketing and general expenses declined by 1 to $363.7m. Research and development had increased 9 per cent to $152.8m.
Investment was made based on the products and services of the future. There was a reduction of 6 per cent in administration expenses at 85.7m. EBIT declined 11% to $254.8m.
The net profit margin was reduced to 17%. Statutory net profit declined by 21 per cent to $161.5m. According to the management, the initial half weighting was always anticipated.
The Nexa system biased earnings to the second half. Currency assumptions were 66c AUD/USD and 56c AUD/EUR. A devalued dollar may reduce profit margin by approximately 30m.
Cochlear’s global footprint highlights revenue growth, workforce scale, and leadership. [ASX]
How Did Cochlear Implants Perform Across Markets?
Cochlear implants had a revenue of 724m and a share of 62 of the sales. Constant currency revenue dropped by 2%. Cleared registrations led to a gradual growth in the developed markets. Nexa had positive responses among professionals.
The half-year performance recorded at the end of the quarter was better in terms of market share. The main markets registered approximately 10 per cent annual unit growth in November and December.
Emerging markets provided growth in terms of volume of more than 15%. Nonetheless, the revenue decreased because of a low-end mix, particularly in China.
The management is enhancing adult referral and senior pathways. The company has also been reorganizing the operations to enhance efficiency. The intention of these steps is to develop the growth capacity that is sustainable.
Cochlear implant surgeries and the increased access to hospitals support unit expansion. [ZenOnco.io]
Services And Acoustics Show Mixed Momentum
Services revenue of 312m fell 1% in constant currency. The developed markets increased by 4 per cent because they had a larger eligible base. Campaigns of awareness helped in the upgrades of the Nucleus 8 Sound Processor.
The emerging markets were slightly weakened. Acoustics revenue was 140m and was down 3% in constant currency. The softening of volumes in the US and UK was a result of high competition.
There was good growth in Western Europe and Australia. The management anticipates that both segments will pick up in H2. The demand should be boosted by new launches and geographic expansion.
Can The Second Half Lift ASX COH HY26 Results?
The outlook is an indication of a better second half with wider Nexa availability. Services are also supposed to increase with the increase in the installed base. Osia and Baha product momentum may favour acoustics. The goal of the company is to assist more than 60,000 individuals to hear in FY26.
The underlying net profit is likely to be at the base of the range of the guidance that is at the $435-460m. To facilitate launches, inventory increased to $566.1m. There was an increase in the working capital and an improvement in cash flow.
Cash flow operations increased to $136.8m. Free cash flow reached $82.7m. The management has been making further investments of approximately 12 per cent of sales in R&D. The plan aims at long-term leadership and an 18% net profit level.
The more extensive availability of Nexa is projected to enhance greater ngs by the management. [ASX]
Cochlear Limited Half-Year Results Reinforce Long-Term Strategy
A transition year, as opposed to structural weakness, is highlighted by the Cochlear Lim half-yearly report. Investment is a disciplined and innovation-oriented activity.
The net cash reserves are flexible in the balance sheet. The implant penetration in the market remains low in the world. That gives space to Expanforon.
The Nexa system has the potential of transforming upgrade cycles and service revenue. Provided contracting becomes normal, the growth could pick up at a fast rate.
Margins and currency effects are things that investors will pay attention to. Nevertheless, the company still has the lead in a niche market that has high barriers to entry.
Also Read: ASX holds strength as tech rebounds; CSL shocks market with CEO exit
FAQs
Q1: What were Cochlear HHY26’s financial results and revenue figures?
A1: Sales revenue reached $1,176m, up 1% reported and down 2% in constant currency.
Q2: How much was the underlying net profit in HY26?
A2: Underlying net profit declined 9% to $195m.
Q3: What dividend did Cochlear declare?
A3: The interim dividend remained steady at $2.15 per share.
Q4: What is the FY26 profit guidance range?
A4: Underlying net profit is guided to $435-460m, at the lower end expected range.
